SG10201702922VA - Isolation and purification of antibodies using protein a affinity chromatography - Google Patents

Isolation and purification of antibodies using protein a affinity chromatography

Info

Publication number
SG10201702922VA
SG10201702922VA SG10201702922VA SG10201702922VA SG10201702922VA SG 10201702922V A SG10201702922V A SG 10201702922VA SG 10201702922V A SG10201702922V A SG 10201702922VA SG 10201702922V A SG10201702922V A SG 10201702922VA SG 10201702922V A SG10201702922V A SG 10201702922VA
Authority
SG
Singapore
Prior art keywords
antibodies
isolation
purification
protein
affinity chromatography
Prior art date
Application number
SG10201702922VA
Other languages
English (en)
Inventor
Robert K Hickman
Qing Huang
Cheryl L Weed
Scott T Ennis
Barbara Perilli-Palmer
Min Wan
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41835469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201702922V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG10201702922VA publication Critical patent/SG10201702922VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201702922VA 2008-10-20 2009-10-20 Isolation and purification of antibodies using protein a affinity chromatography SG10201702922VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19675308P 2008-10-20 2008-10-20

Publications (1)

Publication Number Publication Date
SG10201702922VA true SG10201702922VA (en) 2017-06-29

Family

ID=41835469

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201702922VA SG10201702922VA (en) 2008-10-20 2009-10-20 Isolation and purification of antibodies using protein a affinity chromatography

Country Status (18)

Country Link
US (5) US8895709B2 (https=)
EP (2) EP2921501A1 (https=)
JP (2) JP5808249B2 (https=)
KR (1) KR20110091678A (https=)
CN (2) CN102257006A (https=)
AU (4) AU2009347206C1 (https=)
BR (1) BRPI0920027A2 (https=)
CA (3) CA2911256A1 (https=)
ES (1) ES2535734T3 (https=)
HK (1) HK1209428A1 (https=)
IL (3) IL211918A (https=)
MX (3) MX2011004200A (https=)
NZ (1) NZ592095A (https=)
RU (1) RU2520838C2 (https=)
SG (1) SG10201702922VA (https=)
TW (2) TWI610936B (https=)
WO (1) WO2010141039A1 (https=)
ZA (1) ZA201102523B (https=)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658773B2 (en) * 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
NZ592095A (en) * 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
BRPI0920572A8 (pt) 2008-10-20 2015-10-27 Abbott Lab Inativação viral durante a purificação dos anticorpos
US8262912B1 (en) * 2009-06-05 2012-09-11 Tenfold Technologies, LLC Isolated bioactive compounds and method of use
US9056265B2 (en) 2009-06-05 2015-06-16 Tenfold Technologies, LLC Isolated bioactive compounds and method of use
SI2473617T1 (sl) * 2009-09-01 2020-07-31 F. Hoffmann-La Roche Ag Izboljšano prečiščevanje beljakovin z modificirano elucijo beljakovine A
EP2627425A4 (en) * 2010-10-11 2014-11-05 Abbvie Inc METHODS OF PURIFYING PROTEINS
JP2013544524A (ja) * 2010-12-06 2013-12-19 ターポン バイオシステムズ，インコーポレイテッド 生物学的生成物の連続プロセス法
WO2012125735A1 (en) * 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
WO2012160536A1 (en) * 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
SG195306A1 (en) * 2011-06-08 2013-12-30 Agency Science Tech & Res Purification of biological products by constrained cohydration chromatography
EP2773439A4 (en) * 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR RESOLVING HETEROGENIC ANTIBODY AGGREGATES
SG11201402485UA (en) * 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
BR112014028129A2 (pt) 2012-05-14 2017-06-27 Novo Nordisk As soluções de proteína estabilizadas
TW201348247A (zh) * 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
US20140154270A1 (en) * 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
SG11201407525VA (en) * 2012-06-06 2014-12-30 Emd Millipore Corp Low organic extractable depth filter media processed with solvent extraction method
WO2014004103A1 (en) * 2012-06-29 2014-01-03 Emd Millipore Corporation Methods for inactivating viruses during a protein purification process
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9890191B2 (en) 2012-09-03 2018-02-13 Kaneka Corporation Mixed-mode antibody affinity separation matrix and purification method using the same, and the target molecules
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
WO2014102814A1 (en) * 2012-12-31 2014-07-03 Intas Biopharmaceuticals Limited Process for the purification of fc fusion proteins
AU2014226126B2 (en) 2013-03-08 2019-02-14 Genzyme Corporation Continuous purification of therapeutic proteins
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014142882A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2899449A1 (en) * 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
SI3395423T1 (sl) * 2013-03-14 2023-12-29 Amgen Inc. Odstranjevanje izluženega liganda za afinitetno čiščenje
EP2997036B1 (en) * 2013-05-15 2021-03-03 Medimmune Limited Purification of recombinantly produced polypeptides
KR101569783B1 (ko) * 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
WO2015005960A1 (en) 2013-07-12 2015-01-15 Emd Millipore Corporation Removal of fragments from a sample containing a target protein using activated carbon
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
JPWO2015041218A1 (ja) 2013-09-17 2017-03-02 株式会社カネカ 新規抗体精製方法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎＭｅｔｈｏｄａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）、並びに陽イオン交換基を用いた新規抗体精製法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎｍｅｔｈｏｄｕｓｉｎｇＣａｔｉｏｎＥｘｃｈａｎｇｅｒａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3057616B1 (en) 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
MX2016008498A (es) * 2013-12-27 2016-10-07 Chugai Pharmaceutical Co Ltd Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
PL3116891T3 (pl) 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
US10329323B2 (en) 2014-07-25 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method for purifying antibodies using PBS
JP6630036B2 (ja) * 2014-09-30 2020-01-15 Jsr株式会社 標的物の精製方法、及び、ミックスモード用担体
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
CN105566442A (zh) * 2014-10-11 2016-05-11 江苏泰康生物医药有限公司 一种降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化工艺
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
WO2016149088A1 (en) * 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
DK3334747T5 (da) 2015-08-13 2024-10-07 Amgen Inc Ladet dybdefiltrering af antigenbindende proteiner
KR20180048731A (ko) * 2015-08-20 2018-05-10 제넨테크, 인크. 재조합 폴리펩티드를 제조하기 위한 fkpa의 정제 및 그의 용도
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
MX2018011435A (es) 2016-04-01 2019-01-10 Ucb Biopharma Sprl Metodo para purificacion de proteinas.
BR112018071107A2 (pt) * 2016-04-14 2019-04-16 Lonza Ltd composições e métodos para a detecção de proteínas da célula hospedeira
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
JP7102401B2 (ja) 2016-10-25 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーデータ解析のための方法およびシステム
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
CN110022898B (zh) 2016-12-09 2023-07-04 格利克尼克股份有限公司 用多价Fc化合物治疗炎性疾病的方法
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CR20190291A (es) 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
EP3668985B1 (en) 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
KR102549800B1 (ko) * 2017-08-23 2023-06-30 제이에스알 가부시끼가이샤 크로마토그래피용 담체, 리간드 고정 담체, 크로마토그래피 칼럼, 표적 물질의 정제 방법 및 크로마토그래피용 담체의 제조 방법
CA3073935A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
KR102753090B1 (ko) * 2017-12-21 2025-01-14 젠자임 코포레이션 단백질 a 크로마토그래피 동안 불순물의 향상된 제거를 위한 방법
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
CN108239146A (zh) * 2018-03-26 2018-07-03 江苏中新医药有限公司 一种高纯度rhNGF的制备方法
EP3781941B1 (en) 2018-04-20 2026-01-14 Janssen Biotech, Inc. Chromatography column qualification in manufacturing methods for producing anti-tnf antibody compositions
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
AU2019332764B2 (en) * 2018-08-31 2025-05-29 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111072773A (zh) * 2018-10-19 2020-04-28 菲鹏生物股份有限公司 抗体的纯化方法、抗体和应用
CN111153993B (zh) * 2018-11-07 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗TNF-α单克隆抗体的制备方法
CA3120023A1 (en) * 2018-11-29 2020-06-04 Reform Biologics, Llc Excipient compounds for protein processing
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
TW202112801A (zh) * 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 純化遮蔽抗體之方法
WO2021061790A1 (en) * 2019-09-24 2021-04-01 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
KR20230078748A (ko) * 2020-10-02 2023-06-02 일라이 릴리 앤드 캄파니 항체 정제 공정에서의 숙주 세포 단백질 함량을 감소시키는 방법 및 감소된 숙주 세포 단백질 함량을 가지는 항체 조성물
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
CN113501857A (zh) * 2021-08-17 2021-10-15 沈阳百发科技有限公司 一种高活性重组蛋白的制备方法
CN114292328B (zh) * 2021-12-30 2025-07-25 武汉原谷生物科技有限责任公司 一种来源于美洲羊驼中天然抗体的纯化方法及其应用
JP2025502949A (ja) * 2022-01-24 2025-01-30 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 抗トロンビンｉｉｉのポイントオブケア試験システム
CN115073590A (zh) * 2022-07-08 2022-09-20 杭州艾策生物技术有限公司 一种减少单克隆抗体氧化杂质的深层过滤方法
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
JPS59156299A (ja) 1983-02-28 1984-09-05 Noda Sangyo Kagaku Kenkyusho Ｎ−アセチルヘキソサミンの定量法及びその定量用試薬
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5110913A (en) 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5853714A (en) 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
EP0802257B1 (fr) 1996-04-19 2002-08-21 Societe Des Produits Nestle S.A. Lignée immortalisée de cellules épithéliales du colon humain
AU5082698A (en) * 1996-10-23 1998-05-15 Oravax, Inc Heat inactivation of viruses in antibody preparations
ATE256476T1 (de) * 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
DE69738075T2 (de) 1996-11-27 2008-05-21 Genentech, Inc., South San Francisco Affinitätsreinigung von polypeptiden an einer protein a-matrix
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
IL121900A (en) 1997-10-07 2001-12-23 Omrix Biopharmaceuticals Ltd A method for the purification of immunoglobulins
US20020045207A1 (en) 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
WO1999032605A1 (en) 1997-12-19 1999-07-01 Novo Nordisk A/S Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CA2384880C (en) 1999-09-27 2010-09-21 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors
AU783973B2 (en) 2000-02-08 2006-01-12 Genentech Inc. Improved galactosylation of recombinant glycoproteins
CA2399148A1 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
EP1175931A1 (en) 2000-07-25 2002-01-30 Computer Cell Culture Center S.A. Integration of high cell density bioreactor operation with ultra fast on-line downstream processing
WO2002016590A2 (en) 2000-08-21 2002-02-28 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
US6693173B2 (en) 2000-12-26 2004-02-17 Alpha Therapeutic Corporation Method to remove citrate and aluminum from proteins
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
CN1789416B (zh) 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
ES2321539T3 (es) 2001-06-05 2009-06-08 Genetics Institute, Llc Procedimientos relativos a la purificacion de proteinas altamente anionicas.
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1434857B1 (en) 2001-10-02 2007-08-01 Novo Nordisk Health Care AG Method for production of recombinant proteins in eukaryote cells
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
CA2466881A1 (en) 2001-11-28 2003-06-05 Sandoz Gmbh Cell culture process
ES2322945T5 (es) 2001-12-21 2012-10-17 Immunex Corporation Métodos para purficación de proteína
US20030201229A1 (en) 2002-02-04 2003-10-30 Martin Siwak Process for prefiltration of a protein solution
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
US20030190710A1 (en) 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
RU2304587C2 (ru) * 2002-06-10 2007-08-20 Гуд Байотек Копэрейшн СПОСОБ СЕЛЕКТИВНОГО ВЫДЕЛЕНИЯ АНТИТЕЛ IgY ИЗ ЯИЧНОГО ЖЕЛТКА ПТИЦ ОТРЯДА ГУСЕОБРАЗНЫХ (ВАРИАНТЫ)
EP1543106B1 (en) 2002-07-15 2007-04-11 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
WO2004009776A2 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
US6974681B1 (en) 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
US20040092719A1 (en) * 2002-09-17 2004-05-13 Eszter Birck-Wilson Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds
US7208585B2 (en) 2002-09-18 2007-04-24 Genencor International, Inc. Protein purification
US20040162414A1 (en) 2002-11-22 2004-08-19 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
MXPA05006523A (es) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
MXPA05006522A (es) 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
EP1623019B2 (en) 2003-05-15 2017-01-25 Wyeth LLC Restricted glucose feed for animal cell culture
DK3095793T3 (da) 2003-07-28 2020-05-25 Genentech Inc Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
GB2404665B (en) 2003-08-08 2005-07-06 Cambridge Antibody Tech Cell culture
JP4740138B2 (ja) 2003-10-10 2011-08-03 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 真核生物細胞におけるポリペプチドの大規模生産方法及びそれに適した培養容器
KR101221862B1 (ko) 2003-10-27 2013-01-14 와이어쓰 엘엘씨 하이드록시아파타이트 크로마토그래피를 사용한 고분자량응집체의 제거
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
SE0400886D0 (sv) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
KR20070008645A (ko) 2004-05-04 2007-01-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
PL1807101T3 (pl) 2004-09-30 2016-11-30 Urządzenia i sposoby do zintegrowanego wytwarzania cząsteczek biologicznych w sposób ciągły
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
JP2006143601A (ja) 2004-11-16 2006-06-08 Yamato Yakuhin Kk 血液粘度低下剤
US8728828B2 (en) 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
EP1851305B1 (en) 2005-02-11 2012-01-18 Novo Nordisk Health Care AG Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
EP1869065B1 (en) 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
EP1869067A1 (en) 2005-04-11 2007-12-26 Medarex, Inc. Protein purification using hcic amd ion exchange chromatography
WO2006113743A2 (en) 2005-04-18 2006-10-26 Massachusetts Institute Of Technology Compositions and methods for rna interference with sialidase expression and uses thereof
US7247457B2 (en) 2005-04-26 2007-07-24 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Detection and identification of enteroviruses by semi-nested amplification of the enterovirus VP1 protein
US20090208500A1 (en) 2005-06-03 2009-08-20 Genentech, Inc. Method of producing antibodies with improved function
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
ZA200710330B (en) 2005-06-17 2009-12-30 Wyeth Corp Methods of purifying FC region containing proteins
WO2007022799A1 (en) 2005-08-26 2007-03-01 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
AR058140A1 (es) 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
EP2495308A1 (en) 2005-12-08 2012-09-05 Amgen Inc. Improved production of glycoproteins using manganese
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
US7851438B2 (en) 2006-05-19 2010-12-14 GlycoFi, Incorporated Erythropoietin compositions
JP2010510963A (ja) 2006-06-14 2010-04-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー セラミックヒドロキシアパタイトを使用する抗体の精製方法
WO2008007280A2 (en) 2006-06-28 2008-01-17 Koninklijke Philips Electronics N.V. Assay system and method
EP3255141B1 (en) 2006-07-13 2021-12-01 Wyeth LLC Production of antibodies with improved glycosylation pattern
SI2061803T2 (sl) 2006-08-28 2023-01-31 Ares Trading S.A. Postopek za čiščenje proteinov, ki vsebujejo FC
CN101511387A (zh) 2006-09-08 2009-08-19 惠氏公司 使用亲和色谱法纯化蛋白质的精氨酸洗涤液
AU2007294731B2 (en) * 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
US8911964B2 (en) * 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2008036600A2 (en) 2006-09-18 2008-03-27 Genentech, Inc. Methods of protein production
US20080132688A1 (en) * 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
EP2089424B1 (en) 2006-12-06 2015-07-01 JCR PHARMACEUTICALS Co., LTD. Method for production of human erythropoietin
WO2008079302A2 (en) * 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
NZ580378A (en) * 2007-03-30 2012-11-30 Abbott Lab Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
CA2887752C (en) 2007-04-03 2020-03-24 Vib Vzw Glycosylation of molecules
JP2010524467A (ja) 2007-04-16 2010-07-22 モメンタ ファーマシューティカルズ インコーポレイテッド 規定の糖タンパク質産物および関連の方法
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
WO2008135498A2 (en) 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
CA2687082C (en) 2007-05-11 2014-01-14 Amgen Inc. Improved feed media
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
ES2657055T3 (es) 2007-08-09 2018-03-01 Wyeth Llc Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores
ES2533266T5 (es) 2007-10-30 2018-04-18 Genentech, Inc. Purificación de anticuerpos mediante cromatografía de intercambio catiónico
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
TWM332870U (en) * 2007-11-22 2008-05-21 Delta Electronics Inc Side-edge type backlight module
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
SG187397A1 (en) 2007-12-27 2013-02-28 Baxter Int Cell culture processes
EP2238154B1 (en) 2008-01-18 2015-09-16 Bio-Rad Laboratories, Inc. Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography
JP2011512875A (ja) 2008-03-11 2011-04-28 ジェネンテック， インコーポレイテッド 増強されたａｄｃｃ機能を有する抗体
AU2009236305B2 (en) 2008-04-15 2014-04-10 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2010016943A2 (en) 2008-08-08 2010-02-11 Biogen Idec Ma Inc. Nutrient monitoring and feedback control for increased bioproduct production
BRPI0823046B1 (pt) 2008-08-14 2021-12-14 Genentech, Inc Método para purificar um anticorpo monoclonal de uma composição compreendendo o anticorpo monoclonal e pelo menos uma proteína de ovário de hamster chinês (chop)
KR20110084196A (ko) 2008-09-26 2011-07-21 유레카 쎄라퓨틱스, 인코포레이티드 다양한 글리코실화 패턴을 가진 세포계 및 단백질
MX2011004198A (es) 2008-10-20 2011-05-24 Abbott Lab Anticerpos que unen a il-12 y metodos para purificar los mismos.
NZ592095A (en) * 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
BRPI0920572A8 (pt) 2008-10-20 2015-10-27 Abbott Lab Inativação viral durante a purificação dos anticorpos
MX2011004199A (es) 2008-10-20 2011-05-24 Abbott Lab Anticuerpos que unen a il-18 y metodos para purificar los mismos.
US8058407B2 (en) 2008-10-31 2011-11-15 Wyeth Llc Purification of acidic proteins using ceramic hydroxyapatite chromatography
JP2012511531A (ja) 2008-12-09 2012-05-24 エフ．ホフマン−ラ ロシュ アーゲー 賦形剤不含抗体溶液を得るための方法
JP2012513425A (ja) 2008-12-22 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリンの精製
CA2748807C (en) 2009-01-08 2019-01-29 Ge Healthcare Bio-Sciences Ab Separation method using single polymer phase systems
WO2010102114A1 (en) 2009-03-05 2010-09-10 Biogen Idec Ma Inc. Purification of immunoglobulins
CN102365368B (zh) 2009-03-27 2014-07-30 旭化成医疗株式会社 高浓度单克隆抗体溶液中的病毒去除方法
US8063189B2 (en) 2009-04-13 2011-11-22 Bristol-Myers Squibb Company Protein purification by citrate precipitation
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
KR20120042744A (ko) 2009-05-28 2012-05-03 베링거 인겔하임 인터내셔날 게엠베하 합리적인 세포 배양 공정을 위한 방법
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
BR112012000242B1 (pt) 2009-07-06 2019-07-09 Genentech Inc Métodos para cultivo em batelada de células eucariontes
US20120177640A1 (en) 2009-07-24 2012-07-12 Josef Burg Optimizing the production of antibodies
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
EP3309168A1 (en) 2009-08-06 2018-04-18 F. Hoffmann-La Roche AG Method to improve virus removal in protein purification
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
WO2011024025A1 (en) 2009-08-28 2011-03-03 Avesthagen Limited An erythropoietin analogue and a method thereof
SI2473617T1 (sl) 2009-09-01 2020-07-31 F. Hoffmann-La Roche Ag Izboljšano prečiščevanje beljakovin z modificirano elucijo beljakovine A
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2490780A4 (en) 2009-10-20 2014-04-09 Merck Sharp & Dohme USE OF A MIXED MODE CHROMATOGRAPHY FOR THE DETECTION AND PURIFICATION OF BASIC ANTIBODY PRODUCTS
ES2813398T3 (es) * 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
EP2507627A2 (en) 2009-12-04 2012-10-10 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
US8277649B2 (en) 2009-12-14 2012-10-02 General Electric Company Membranes and associated methods for purification of antibodies
ES2982297T3 (es) 2009-12-18 2024-10-15 Novartis Ag Método de cromatografía de afinidad
WO2011087301A2 (ko) 2010-01-15 2011-07-21 성균관대학교산학협력단 기체 및 수분 차단용 그래핀 보호막, 이의 형성 방법 및 그의 용도
BR112012025641A2 (pt) 2010-04-06 2019-09-24 Heliae Dev Llc métodos e sistemas para produzir biocombustíveis.
WO2011127322A1 (en) 2010-04-07 2011-10-13 Momenta Pharmaceuticals, Inc. High mannose glycans
PL2563906T3 (pl) 2010-04-26 2018-04-30 Novartis Ag Sposób hodowli komórek cho
CA2797356C (en) 2010-04-26 2020-12-29 Novartis Ag Improved cell culture medium
CA2800728C (en) 2010-05-28 2020-10-27 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
SG187198A1 (en) 2010-08-05 2013-03-28 Amgen Inc Dipeptides to enhance yield and viability from cell cultures
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
JP6010030B2 (ja) * 2010-09-20 2016-10-19 アッヴィ・インコーポレイテッド 疑似移動床クロマトグラフィーを使用する抗体の精製
EP2627425A4 (en) * 2010-10-11 2014-11-05 Abbvie Inc METHODS OF PURIFYING PROTEINS
WO2012050175A1 (ja) 2010-10-15 2012-04-19 日本ケミカルリサーチ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
EP2450375A1 (en) 2010-11-09 2012-05-09 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
SG191071A1 (en) 2010-12-08 2013-07-31 Amgen Inc Ion exchange chromatography in the presence of an amino acid
KR101574864B1 (ko) 2010-12-21 2015-12-11 에프. 호프만-라 로슈 아게 이소폼이 농축된 항체 제제 및 그의 제조 방법
CA2829110C (en) 2011-03-06 2019-01-15 Merck Serono S.A. Low fucose cell lines and uses thereof
KR20140022845A (ko) 2011-03-25 2014-02-25 제넨테크, 인크. 신규 단백질 정제 방법
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
CN105189735B (zh) 2011-04-29 2019-04-12 拜康研究有限公司 在培养期间减少乳酸累积的方法和生产多肽的方法
US20120283419A1 (en) 2011-05-03 2012-11-08 Avantor Performance Materials, Inc. Separation of protein monomers from aggregates by solid weak anion exchange support functionalized with amine moieties
WO2012158551A1 (en) 2011-05-13 2012-11-22 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
PT2837680T (pt) 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
WO2013006461A1 (en) 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
WO2013013013A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
HK1199272A1 (en) 2011-10-19 2015-06-26 Roche Glycart Ag Separation method for fucosylated antibodies
WO2013158279A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9085618B2 (en) * 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same

Also Published As

Publication number Publication date
NZ592095A (en) 2013-01-25
US20140255423A1 (en) 2014-09-11
ES2535734T3 (es) 2015-05-14
AU2009347206B2 (en) 2015-08-20
TWI610936B (zh) 2018-01-11
CA2738498A1 (en) 2010-12-09
RU2520838C2 (ru) 2014-06-27
CN105111309A (zh) 2015-12-02
KR20110091678A (ko) 2011-08-12
US8895709B2 (en) 2014-11-25
US9018361B2 (en) 2015-04-28
AU2018203810A1 (en) 2018-06-21
MX2018014395A (es) 2020-07-29
MX343087B (es) 2016-10-14
US20100135987A1 (en) 2010-06-03
IL211918A (en) 2016-03-31
MX2011004200A (es) 2011-05-24
ZA201102523B (en) 2011-12-28
JP2015042645A (ja) 2015-03-05
EP2350127A1 (en) 2011-08-03
AU2015207915A1 (en) 2015-08-20
RU2011120191A (ru) 2012-11-27
IL244157A0 (en) 2016-04-21
AU2015207915C1 (en) 2016-12-08
EP2350127B1 (en) 2015-01-28
IL232601A0 (en) 2014-06-30
CA2911256A1 (en) 2010-12-09
AU2009347206C1 (en) 2016-12-08
AU2016222301A1 (en) 2016-09-15
AU2015207915B2 (en) 2016-06-02
JP5808249B2 (ja) 2015-11-10
TW201024318A (en) 2010-07-01
AU2009347206A1 (en) 2010-12-09
TW201634476A (zh) 2016-10-01
HK1209428A1 (en) 2016-04-01
AU2009347206A8 (en) 2011-05-26
US20150210735A1 (en) 2015-07-30
US20160083452A1 (en) 2016-03-24
WO2010141039A1 (en) 2010-12-09
CA2932207A1 (en) 2010-12-09
IL211918A0 (en) 2011-06-30
CN102257006A (zh) 2011-11-23
US20170158760A1 (en) 2017-06-08
JP2012506383A (ja) 2012-03-15
BRPI0920027A2 (pt) 2015-10-06
EP2921501A1 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
IL244157A0 (en) Isolation and purification of antibodies using protein a affinity chromatography
ZA201202720B (en) Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
SG2013061528A (en) Methods for purifying antibodies using protein a affinity chromatography
IL205257A0 (en) Anti-rsv g protein antibodies
IL210283A0 (en) Prostaglandin e2 binding proteins and uses thereof
PL2190984T3 (pl) Sposoby i zestawy do oczyszczania i wykrywania glikozylowanego IgG
IL197479A0 (en) High affinity human antibodies to human il-4 receptor
PL1786273T3 (pl) Schematy sekwencyjnego izolowania i oczyszczania białek sposobem chromatografii powinowactwa
EP2184356A4 (en) METHOD FOR BONDING PROTEIN TO MEDIA USING TAMAVIDINE
IL215014A0 (en) Antibody molecules having binding specificity for human il-13
EP2182003A4 (en) FOR BINDING IMMOBILULATED PEPTIDE
HK1175182A (en) Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
GB0709037D0 (en) Isolation of proteins
IL182717A0 (en) Antibodies to interferon - ??/?? binding protein
GB0608602D0 (en) Analysis of proteins
EP2540742A4 (en) MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF
AU2009905049A0 (en) Affinity Ligands and Methods for Protein Purification